# Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

> **NCT02898116** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 2 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Carcinoma
- NSCLC

## Interventions

- **DRUG:** Ensartinib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02898116
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2017-08-04
- **Final completion:** 2017-08-04
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898116, "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02898116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*